Go to
JCI Insight
Citations to this article
Patti E. Gravitt
Published December 1, 2011
Citation Information: J Clin Invest. 2011;121(12):4593-4599. https://doi.org/10.1172/JCI57149.
Citation Information: J Clin Invest. 2011;121(12):4593-4599. https://doi.org/10.1172/JCI57149.
Abstract
The discovery that certain high-risk strains of human papillomavirus (HR-HPV) cause nearly 100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by promoting the development of viral vaccines. Although the efficacy of these vaccines has already been demonstrated, a complete understanding of viral latency and natural immunity is lacking, and solving these mysteries could help guide policies of cervical cancer screening and vaccine use. Here, we examine the epidemiological and biological understanding of the natural history of HPV infection, with an eye toward using these studies to guide the implementation of cervical cancer prevention strategies.
Authors
Patti E. Gravitt
Total citations by year
Citation information
Citations to this article in year 2012 (11)
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)